Biotech success, 2002 Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech success, 2002

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who started this subject	2/27/2002 8:15:01 AM
From: scott_jiminez	Read Replies (1) of 117

Fascinating.... ============= Boston, Feb 27, 2002 (MidnightTrader via COMTEX) -- ImClone Systems (IMCL) is charging higher this morning on 19,100 Instinet shares following wire service reports late Tuesday night that U.S. regulators informed the company they would review ImClone's request to market its cancer drug, Erbitux, if the company resubmits data from its U.S. trial along with new data from trials in Europe. ImClone and partner Bristol Myers Squibb (BMY) met with the FDA Tuesday as part of their efforts to have regulators re-examine the data after the FDA refused to consider the drug last year. Price: 22.15, Change: +6.63, Percent Change: +42.0% =============

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next